Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 10/2002

01-08-2002 | Review Article

Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors

Authors: Dr Michael W. Jann, Kara L. Shirley, Gary W. Small

Published in: Clinical Pharmacokinetics | Issue 10/2002

Login to get access

Abstract

Cholinesterase inhibitors are the ‘first-line’ agents in the treatment of Alzheimer’s disease. This article presents the latest information on their pharmacokinetic properties and pharmacodynamic activity.
Tacrine was the first cholinesterase inhibitor approved by regulatory agencies, followed by donepezil, rivastigmine and recently galantamine. With the exception of low doses of tacrine, the cholinesterase inhibitors exhibit a linear relationship between dose and area under the plasma concentration-time curve. Cholinesterase inhibitors are rapidly absorbed through the gastrointestinal tract, with time to peak concentration usually less than 2 hours; donepezil has the longest absorption time of 3 to 5 hours. Donepezil and tacrine are highly protein bound, whereas protein binding of rivastigmine and galantamine is less than 40%. Tacrine is metabolised by hepatic cytochrome P450 (CYP) 1A2, and donepezil and galantamine are metabolised by CYP3A4 and CYP2D6. Rivastigmine is metabolised by sulfate conjugation.
Two cholinesterase enzymes are present in the body, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Tacrine and rivastigmine inhibit both enzymes, whereas donepezil and galantamine specifically inhibit AChE. Galantamine also modulates nicotine receptors, thereby enhancing acetylcholinergic activity at the synapse. These different pharmacological profiles provide distinctions between these agents. Cholinesterase inhibitors show a nonlinear relationship between dose and cholinesterase inhibition, where a plateau effect occurs. Cholinesterase inhibitors display a different profile as each agent achieves its plateau at different doses.
In clinical trials, cholinesterase inhibitors demonstrate a dose-dependent effect on cognition and functional activities. Improvement in behavioural symptoms also occurs, but without a dose-response relationship. Gastrointestinal adverse events are dose-related. Clinical improvement occurs with between 40 and 70% inhibition of cholinesterase. A conceptual model for cholinesterase inhibitors has been proposed, linking enzyme inhibition, clinical efficacy and adverse effects. Currently, measurement of enzyme inhibition is used as the biomarker for cholinesterase inhibitors. New approaches to determining the efficacy of cholinesterase inhibitors in the brain could involve the use of various imaging techniques.
The knowledge base for the pharmacokinetics and pharmacodynamics of cholinesterase inhibitors continues to expand. The increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer’s disease.
Literature
1.
2.
Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer’s disease. Drugs 1997; 53: 752–68PubMedCrossRef
3.
Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging 1999; 14: 359–73PubMedCrossRef
4.
VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer’s disease in the elderly. Drugs Aging 2000; 16: 123–36CrossRef
5.
6.
Practico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–85CrossRef
7.
8.
Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer’s disease and related disorders. JAMA 1997; 278: 1363–71PubMedCrossRef
9.
Taylor P. Anticholinesterase agents. In: Hardman JG, Limbird LE, editors. Goodman’s and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 161–75
10.
Imbimbo BP. Pharmacodynamic tolerability relationships of cholinesterase inhibitors for Alzheimer’s disease. CNS Drugs 2001; 15: 375–90PubMedCrossRef
11.
Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4–15PubMed
12.
Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother 1994; 28: 744–51PubMed
13.
Parnetti L. Clinical pharmacokinetic of drugs for Alzheimer’s disease. Clin Pharmacokinet 1995; 29: 110–29PubMedCrossRef
14.
Forsyth DR, Wilcock GK, Morgan RA, et al. Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 1989; 46: 634–41PubMedCrossRef
15.
Cutler NR, Sedman AJ, Prior P, et al. Steady-state pharmacokinetics of tacrine in patients with Alzheimer’s disease. Psychopharmacol Bull 1990; 26: 231–4PubMed
16.
Hartvig P, Askmark H, Aquilonius SM, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990; 38: 259–63PubMedCrossRef
17.
Madden S, Spaldin V, Park BK. Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 1995; 28: 449–57PubMedCrossRef
18.
Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease. Drug Saf 1998; 19: 465–80PubMedCrossRef
19.
Wagstaff A, McTavish D. Tacrine: a review of its pharmacological and pharmacokinetic properties and therapeutic potential in Alzheimer’s disease. Drugs Aging 1994; 4: 1–31CrossRef
20.
Makela PM, Truman CA, Ford JM, et al. Plasma protein binding characteristics of tacrine hydrochloride (THA) [abstract]. Br J Clin Pharmacol 1994; 38: 489PCrossRef
21.
Grothe DR, Piscitelli SC, Dukoff R, et al. Penetration of tacrine into cerebrospinal fluid in patients with Alzheimer’s disease. J Clin Psychopharmacol 1998; 18: 78–81PubMedCrossRef
22.
Simon T, Becquemont L, Mary-Krause M, et al. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67: 432–7PubMedCrossRef
23.
McGleenon BM, Dyman KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol 1999; 48: 471–80PubMedCrossRef
24.
Murphy MF, Hardiman ST, Nash RJ, et al. Evaluation of HP-029 (velnacrine maleate) in Alzheimer’s disease. Ann N Y Acad Sci 1991; 640: 253–62PubMed
25.
26.
27.
Rogers SL, Friedhoff LT. Pharmacokinetics and pharmacodynamic profile of donepezil HCL following single oral dose. Br J Clin Pharmacol 1998; 46 Suppl. 1: 1–6PubMedCrossRef
28.
Rogers SL, Cooper NM, Sukovarty R, et al. Pharmacokinetics and pharmacodynamic profile of donepezil HC1 following multiple oral dose. Br J Clin Pharmacol 1998; 46 Suppl. 1: 7–12PubMedCrossRef
29.
Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer’s disease. Arch Intern Med 1998; 158: 1021–31PubMedCrossRef
30.
Shintani EY, Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm 1997; 54: 2805–10PubMed
31.
Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C donepezil in healthy volunteers: a single dose study. Br J Clin Pharmacol 1998; 46 Suppl. 1: 19–24PubMedCrossRef
32.
Ohnishi A, Mihara M, Kamakura H, et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 1993; 33: 1086–91PubMed
33.
Tiseo PJ, Vargas R, Perdono CA, et al. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired hepatic function. Br J Clin Pharmacol 1998; 46 Suppl. 1: 51–5PubMedCrossRef
34.
Tiseo PJ, Foley K, Friedhoff LT, et al. An evaluation of the pharmacokinetics of donepezil hydrochloride in patients with impaired moderate to severe renal impairment. Br J Clin Pharmacol 1998; 46 Suppl. 1: 56–60PubMedCrossRef
35.
Jann MW. Rivastigmine, anew generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000;20: 1–12PubMedCrossRef
36.
Sramek JJ, Anand R, Wardie TS, et al. Safety/tolerability trial of SDZ 713 in patients with probable Alzheimer’s disease. Life Sci 1996; 58: 1201–7PubMedCrossRef
37.
38.
Kennedy JS, Polinsky RJ, Johnson B, et al. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 1999; 19: 513–21PubMedCrossRef
39.
Cutler NR, Polinsky RJ, Sramek JJ, et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 1998; 97: 244–50PubMedCrossRef
40.
Schran HF, Habucky K, Mancione LC, et al. The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713 [abstract]. Pharm Res 1996; 13: S–428
41.
42.
Mihailova D, Yamboliev I, Zhivkova Z, et al. Pharmacokinetic of galantamine hydrobromide after single subcutaneous and oral dosage in humans. Pharmacology 1989; 39: 50–8PubMedCrossRef
43.
Johansson IM, Nordberg A. Pharmacokinetic studies of cholinesterase inhibitors. Acta Neurol Scand 1993; 149: 22–5
44.
Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galantamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991; 50: 420–8PubMedCrossRef
45.
Davidson P, Blennow K, Andreasen N, et al. Differential increase in CSF acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 2001; 30: 157–60CrossRef
46.
Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galantamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661–8PubMedCrossRef
47.
Fontana RJ, de Vries TM, Woolf TF, et al. Caffeine based measures of CYP 1A2 correlate with oral clearance of tacrine in patients with Alzheimer’s disease. Br J Clin Pharmacol 1998; 46: 221–8PubMedCrossRef
48.
Ford JM, Truman CA, Wilcock GK, et al. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer’s disease. Clin Pharmacol Ther 1993; 53: 691–5PubMedCrossRef
49.
Welty D, Pool W, Woolf T, et al. The effect of smoking on the pharmacokinetics and metabolism of Cognex in healthy volunteers [abstract]. Pharm Res 1993; 10: S344
50.
Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46 Suppl. 1: 40–4PubMedCrossRef
51.
Forgue ST, Reece PA, Sedman AJ, et al. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1998; 59: 444–9CrossRef
52.
Laine K, Palovaara S, Tapanainen P, et al. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther 1999; 66: 602–8PubMed
53.
Becquemont L, LeBot MA, Riche C, et al. Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Pharmacogenetics 1998; 8: 101–8PubMedCrossRef
54.
Becquemont L, Ragueneau I, LeBot MA, et al. Influence of the CYP 1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619–27PubMedCrossRef
55.
Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25–9PubMedCrossRef
56.
Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HC1 and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 30–4PubMedCrossRef
57.
Carrier L. Donepezil and paroxetine: possible drug interaction [letter]. J Am Geriatr Soc 1999; 47: 1037PubMed
58.
Rojas-Fernandez C, Fisher C. Drug interactions with donepezil. J Am Geriatr Soc 2000; 48: 597–8PubMed
59.
Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 2000; 48: 1659–63PubMed
60.
Ravic M, Warrington S, Boyce M. The safety and pharmacokinetics of thioridazine during co-administration with donepezil [abstract]. Clin Pharmacol Ther 2001; 69: P44
61.
Reyes JF, Preskorn S, Khan A, et al. Pharmacokinetics of donepezil and risperidone in males with schizophrenia [abstract]. Clin Pharmacol Ther 2001; 69: P44
62.
Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HC1 and theophylline: assessment of pharmacokinetic changes following multiple doses in healthy volunteers. Br J Clin Pharmacol 1998; 46 Suppl. 1: 35–9PubMedCrossRef
63.
Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HC1 on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 1998; 46 Suppl. 1: 45–50PubMedCrossRef
64.
Grosssberg GT, Stamelin HB, Messina JC, et al. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty two classes of medications. Int J Geriatr Psychiatr 2000; 15: 242–7CrossRef
65.
Jann MW. Preclinical pharmacology of metrifonate. Pharmacotherapy 1998; 18(2 pt 2): 55S–67S
66.
Rivastigmine (Exelon®) package insert. Physician’s desk reference. Montvale (NJ): Medical Economic Company, Inc., 2000
67.
Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxic 1994; 34: 281–320CrossRef
68.
Guillozet AL, Smiley JF, Mash DC, et al. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42: 909–18PubMedCrossRef
69.
Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer’s disease?. CNS Drugs 2001; 15: 85–91PubMedCrossRef
70.
Cummings JL. Metrifonate: overview of safety and efficacy. Pharmacotherapy 1998; 18(2 pt 2): 43S–6S
71.
Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment for Alzheimer’s disease. Biol Psychiatry 2001; 49: 279–88PubMedCrossRef
72.
Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol 1998; 38: 610–7PubMed
73.
Rogers SL, Farlow MR, Doody RS, et al. A 24-week double blind placebo controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45PubMedCrossRef
74.
Davis CS. Statistical issues in the design and analysis of clinical trials in Alzheimer’s disease. Drug Inf J 1996; 30: 339–50CrossRef
75.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64PubMed
76.
Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s disease cooperative study: clinical global impression of change. Alzheimer Dis Assoc Disord 1997; 11(S2): S22–32PubMedCrossRef
77.
Giacobini E. Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications. Neurochem Lett 1998; 32: 413–9CrossRef
78.
79.
80.
DeJong R, Osterlund OW, Roy GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11: 545–54PubMed
81.
Krall WJ, Sramek JJ, Cutler NR. Cholinesterase inhibitors: a therapeutic strategy for Alzheimer’s disease. Ann Pharmacother 1999; 33: 441–50PubMedCrossRef
82.
Farlow MR, Evans RM. Pharmacologie treatment of cognition in Alzheimer’s dementia. Neurology 1998; 51 Suppl. 1: S36–44PubMedCrossRef
83.
Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91PubMedCrossRef
84.
Corey-Bloom J, Anand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1999; 1: 55–65
85.
Tariot PN, Solomon PR, Morris JC, et al. A 5-month randomized placebo controlled trial of galantamine in AD. Neurology 2000; 54: 2269–76PubMedCrossRef
86.
Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer’s disease. Int J Geriatr Psychopharmacol 2000; 2: 68–72
87.
Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized placebo controlled trial with a 6-month extension. Neurology 2000; 54: 2261–8PubMedCrossRef
88.
Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer’s disease: an open label study. J Geriatr Psychiatry Neurol 1996; 9: 1–6PubMed
89.
Weiner MF, Martin-Cook K, Foster BM, et al. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry 2000; 61: 487–92PubMedCrossRef
90.
Hunter R, Wyper DJ, Patterson J, et al. Cerebral pharmacodynamics of physostigmine in Alzheimer’s disease investigated using SPECT. Br J Psychiatry 1991; 158: 351–7PubMedCrossRef
91.
Cohen MB, Fitten LJ, Lake RR, et al. SPECT brain imaging in Alzheimer’s disease during treatment with oral THA and lecithin. Clin Nucl Med 1992; 17: 312–5PubMedCrossRef
92.
Bookheimer SY, Strojwas H, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. New Engl J Med 2000; 343: 450–6PubMedCrossRef
93.
Small GW. Structural and functional imaging of Alzheimer’s disease. In: Charney DS, Coyle J, Davis K, et al., editors. Psychopharmacology: the fifth generation of progress. Philadelphia: Lippincott, Williams and Wilkens, 2002: 1231–42
94.
Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9PubMedCrossRef
95.
Burns A, Rosser M, Hecker J, et al. The effect of donepezil in Alzheimer’s disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44PubMedCrossRef
96.
Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. BMJ 1999; 318: 633–40
97.
Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA 1994; 271: 992–8PubMedCrossRef
98.
Green VJ, Pirmohamed M, Kitteringham NR, et al. Glutathione S-transferase μ genotype (GSTM 1*0) in Alzheimer’s patients with tacrine transaminitis. Br J Clin Pharmacol 1995; 39: 411–5PubMedCrossRef
99.
American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997; 154(5): 1–39
100.
Steele CD, Steinberg M, Miles G, et al. Recognition and management of early Alzheimer’s disease. J Clin Outcome Management 1999; 6: 52–68
Metadata
Title
Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors
Authors
Dr Michael W. Jann
Kara L. Shirley
Gary W. Small
Publication date
01-08-2002
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2002
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200241100-00003

Other articles of this Issue 10/2002

Clinical Pharmacokinetics 10/2002 Go to the issue

Correspondence

Aminoglycoside Dosage Regimens After Therapeutic Drug Monitoring

Review Article

Clinical Pharmacokinetics of Cytarabine Formulations

Review Article

Enterohepatic Circulation

Review Article

Clinical Role of Protein Binding of Quinolones

Leading Article

Considerations in the Use of Cerebrospinal Fluid Pharmacokinetics to Predict Brain Target Concentrations in the Clinical Setting